<DOC>
	<DOCNO>NCT02453685</DOCNO>
	<brief_summary>This trial conduct globally . The aim trial compare stepwise insulin intensification biphasic insulin aspart ( BIAsp ) 30 basal-bolus therapy insulin glargine insulin aspart insulin naïve type 2 diabetic patient inadequately control oral anti-diabetic therapy .</brief_summary>
	<brief_title>A Study Compare Insulin Intensification Biphasic Insulin Aspart 30 Insulin Analogues ( Insulin Glargine Insulin Aspart ) Insulin naïve Type 2 Diabetic Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Informed consent obtain trialrelated activity . Trialrelated activity procedure carry part trial , include activity determine suitability trial Male female , age least 18 year time signing informed consent Type 2 diabetes subject clinically diagnose least 6 month prior screen Treatment stable daily dose ( least 90 day prior screen ) : Metformin ( equal 1000 mg maximum tolerate dose document patient medical record ) Sulfonylurea willing discontinue oral antidiabetic drug contain insulin secretagogues , DPP4i ( dipeptidyl peptidase4 inhibitor ) , SGLT2 ( sodium glucose cotransporter 2 ) , colesevelam , bromocriptin and/or combination product randomisation Insulinnaïve . Short term insulin treatment acute illnesses total 14 day less allowed prior insulin treatment gestational diabetes HbA1c ( glycosylated haemoglobin ) 7.09.5 % ( inclusive ) analyse central laboratory Willing consume 3 main meal daily ( morning , midday evening ) throughout entire trial . The definition 'main meal ' accord investigator 's discretion Anticipated initiation change concomitant medication know affect weight glucose metabolism , excess 14 day ( i.e . sibutramine , orlistat , thyroid hormone , systemic corticosteroid weight loss/modifying agent ) Impaired liver function , define ALT ( alanine aminotransferase ) least 2.5 time upper limit normal ( central laboratory value measure screen visit ) Inadequately treat high blood pressure define Class 2 hypertension high ( i.e . systolic blood pressure equal 160 mm Hg diastolic equal 100 mm Hg ) accordance National High Blood Pressure Education Program , 7th Joint National Committee1 ESH/ESC 2013 Guidelines2 Within past 180 day prior randomisation , follow : Myocardial Infarction , stroke hospitalization unstable angina /or transient ischemic attack</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>